PUBLISHER: DelveInsight | PRODUCT CODE: 1226621
PUBLISHER: DelveInsight | PRODUCT CODE: 1226621
"PIQRAY Drug Insight and Market Forecast - 2032" report provides comprehensive insights about PIQRAY for ER +ve HER2-ve Breast Cancer in the United States. A detailed picture of the PIQRAY for ER+ve HER2-ve Breast Cancer in the United States for the study period 2019-2032 is provided in this report along with a detailed description of the PIQRAY for ER+ve HER2-ve Breast Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the PIQRAY market forecast, analysis for ER+ve HER2-ve Breast Cancer in the United States, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in ER+ve HER2-ve Breast Cancer.
PIQRAY (BYL719; ALPESLIB) is an orally bioavailable, alpha-specific PI3K inhibitor developed by Novartis. In breast cancer cell lines harboring PIK3CA mutations, BYL719 has been shown to potentially inhibit the PI3K pathway and have antiproliferative effects. In addition, cancer cell lines with PIK3CA mutations were more sensitive to BYL719 than those without the mutation across a broad range of different cancers.
The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. This drug comes in three dosage forms: 50 mg, 150 mg, and 200 mg.
Alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K), with inhibitory activity predominantly against PI3Kα. Gain-of-function mutations in the PI3K catalytic α- subunit gene (PIK3CA) activate PI3K and Akt signaling, resulting in cellular transformation and tumor formation in vitro and in vivo. In breast cancer cell lines, alpelisib inhibited the phosphorylation of PI3K downstream targets, including Akt, and showed activity in cell lines harboring a PIK3CA mutation. In vivo, alpelisib inhibited the PI3K/Akt signaling pathway and reduced tumor growth in xenograft models, including models of breast cancer. PI3K inhibition by alpelisib treatment has been shown to induce an increase in estrogen receptor (ER) transcription in breast cancer cells. The combination of alpelisib and fulvestrant demonstrated increased antitumor activity compared to either treatment alone in xenograft models derived from ER+, PIK3CA-mutated breast cancer cell lines.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
PIQRAY Analytical Perspective by DelveInsight
This report provides a detailed market assessment of PIQRAY in ER+ve HER2-ve Breast Cancer in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of PIQRAY in ER+ve HER2-ve Breast Cancer covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions